Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Interest Coverage Ratio: 2021-2025

Historic Interest Coverage Ratio for SAB Biotherapeutics (SABS) over the last 5 years, with Sep 2025 value amounting to -292.87.

  • SAB Biotherapeutics' Interest Coverage Ratio fell 102.08% to -292.87 in Q3 2025 from the same period last year, while for Sep 2025 it was -174.11, marking a year-over-year decrease of 9.42%. This contributed to the annual value of -134.77 for FY2024, which is 11.60% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Interest Coverage Ratio stood at -292.87, which was down 93.64% from -151.25 recorded in Q2 2025.
  • In the past 5 years, SAB Biotherapeutics' Interest Coverage Ratio registered a high of 10.82 during Q1 2021, and its lowest value of -292.87 during Q3 2025.
  • Moreover, its 3-year median value for Interest Coverage Ratio was -144.92 (2024), whereas its average is -148.06.
  • In the last 5 years, SAB Biotherapeutics' Interest Coverage Ratio tumbled by 960.35% in 2022 and then spiked by 41.73% in 2024.
  • SAB Biotherapeutics' Interest Coverage Ratio (Quarterly) stood at -110.81 in 2021, then climbed by 19.12% to -89.62 in 2022, then plummeted by 170.40% to -242.35 in 2023, then surged by 41.73% to -141.22 in 2024, then slumped by 102.08% to -292.87 in 2025.
  • Its Interest Coverage Ratio stands at -292.87 for Q3 2025, versus -151.25 for Q2 2025 and -154.85 for Q1 2025.